IL13 and neoplasm: For example, immunosuppressive ILC2 may release IL-13 to stimulate the development of immunosuppressive myeloid–derived suppressor cells, whereas inflammatory ILC2 produce IL-5 to enhance the cytotoxic activity of eosinophils to suppress tumor progression (41–43).